Swift Comments on Repercussions of U.S. Withdrawal from Iran Nuclear Pact
May 11, 2018
Washington Examiner
Partner Christopher Swift was quoted in a Washington Examiner article, “Business braces for fallout from Trump’s go-it-alone Iran strategy,” about expected changes in the global business climate in the wake of President Trump’s decision to scuttle the Iran nuclear deal.
Swift said the business environment is essentially returning to many of the conditions in effect before the 2015 signing of the Iran deal. “Suddenly these foreign subsidiaries of U.S. corporations become subject to primary sanctions again,” he said. “And everybody else in Europe is going to be subject to secondary sanctions again.”
Swift said the business environment is essentially returning to many of the conditions in effect before the 2015 signing of the Iran deal. “Suddenly these foreign subsidiaries of U.S. corporations become subject to primary sanctions again,” he said. “And everybody else in Europe is going to be subject to secondary sanctions again.”
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."